A lector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like ...

Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy ...

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands ...

After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus.

Join us as we dissect Summit Therapeutics' potential in the biotech sector. Can their promising drug Ansuvimab overcome the ...

The company’s technology, a modified herpes simplex virus used to deliver gene therapies, was given the FDA’s new designation ...

The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...

While insider buying is typically slower when markets are near all-time highs and when earnings-reporting season is in full ...

Leverage RWE strategically to build regulator-ready submissions.

BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.

Shares of mid-cap oncology specialist Exelixis are worth about $39 each right now. The biotech generates steady revenue and ...

Swiss investment company BB Biotech reported an outstanding third quarter in 2025. Here’s why.